Sarepta Therapeutics (SRPT) Liabilities and Shareholders Equity (2010 - 2026)

Sarepta Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $3.2 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 8.27% year-over-year to $3.2 billion; the TTM figure through Mar 2026 stood at $13.7 billion (down 5.2% YoY), while the FY2025 annual figure was $3.3 billion, down 15.48% from the prior year.
• Liabilities and Shareholders Equity was $3.2 billion for Q1 2026 at Sarepta Therapeutics, down from $3.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.0 billion in Q4 2024 to a low of $3.0 billion in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $3.3 billion across 5 years, with a median of $3.2 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity climbed 21.4% in 2024, then slipped 15.48% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.1 billion in 2022, then grew by 4.35% to $3.3 billion in 2023, then climbed by 21.4% to $4.0 billion in 2024, then retreated by 15.48% to $3.3 billion in 2025, then dropped by 5.1% to $3.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $3.2 billion (Q1 2026), $3.3 billion (Q4 2025), and $3.5 billion (Q3 2025), per Business Quant data.